Dr. Johnson on the Future of Immunotherapy in Lung Cancer

Melissa L. Johnson, MD
Published: Saturday, May 27, 2017



Melissa L. Johnson, MD, medical oncologist, Sarah Cannon Research Institute, discusses potential immunotherapy regimens for patients with lung cancer.

Pembrolizumab (Keytruda) is approved for patients in the frontline setting for tumors that express high PD-L1 expression, which is only seen in 30% of patients.

Chemotherapy plus immunotherapy or PD-L1 inhibitors in combination with other checkpoint inhibitors are currently being investigated to treat the remaining patients in the frontline setting.

PD-1 plus anti CTLA-4 has already been approved for the treatment of patients with metastatic melanoma. There are ongoing trials evaluating that strategy for patients with lung cancer, explains Johnson.
 


Melissa L. Johnson, MD, medical oncologist, Sarah Cannon Research Institute, discusses potential immunotherapy regimens for patients with lung cancer.

Pembrolizumab (Keytruda) is approved for patients in the frontline setting for tumors that express high PD-L1 expression, which is only seen in 30% of patients.

Chemotherapy plus immunotherapy or PD-L1 inhibitors in combination with other checkpoint inhibitors are currently being investigated to treat the remaining patients in the frontline setting.

PD-1 plus anti CTLA-4 has already been approved for the treatment of patients with metastatic melanoma. There are ongoing trials evaluating that strategy for patients with lung cancer, explains Johnson.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x